Abstract: The present invention relates to methods of improving the environment within a poultry farming facility including reducing ammonia production in a poultry facility, inhibiting urease enzymes in poultry litter, reducing levels of pathogenic bacteria in poultry litter, improving productivity of poultry farms, reducing or preventing pododermatitis in poultry reared in mass production poultry facilities and controlling pests in poultry litter. Compositions, suitable for use in such methods, comprising at least one microorganism of the genus Bacillus and at least one biosurfactant wherein the biosurfactant is present in an amount of 2 mg/L to 7000 mg/L are also described.

Abstract: The present invention provides a method for producing hepatic stem/progenitor cells from mammal hepatocytes, comprising bringing a TGF?-receptor inhibitor, and optionally a GSK3 inhibitor and/or a ROCK inhibitor into contact with the hepatocytes in vitro.

Abstract: The present invention relates to a biologically active medical device, which includes a matrix seeded with progenitor cells, and then covered by ciliated tissue. The matrix is capable of enabling cellular migration. The ciliated tissue is ependymal cells that express at least one of tight junctional complexes, zonula adherens, and gap junctions. The progenitor cells include subpendymal progenitor cells. In some cases the progenitor cells include stem cells, and the ciliated tissue includes at least one of Choroid cells, tanacytes, and circumventricular organs. In some embodiments, the medical device is oriented into a tubular structure in order to form a cerebrospinal shunt. Additional cells and structures may be imbedded within the matrix, such as glia, endothelial cells, stem cells, and blood vessels. The medical device may also be incorporated into a bioreactor including a flexible inner tube defining an anthropomorphically shaped lumen.

Abstract: An exemplary tissue array, and a method for producing the same, can be provided which can include providing an accepter biological structure(s), providing a donor tissue(s), removing a portion(s) of the donor tissue(s), and removing a portion(s) of the accepter biological structure(s). The removed portion(s) of the accepter biological structure(s) can have a size that is substantially similar to a size of the removed portion(s) of the donor tissue(s). The removed portion(s) of the donor tissue(s) can be inserted into the accepter biological structure(s) at a location substantially corresponding to the removed portion(s) of the accepter biological structure(s).

Abstract: The present invention provide a method for detecting a test substance utilizing a color development caused by an enzyme reaction, or a color development caused by a specific interaction such as an antigen-antibody reaction and an enzyme reaction, the test substance being detected rapidly, sensitively and quantitatively without using a spectroscopic measurement device. The method for measuring a concentration of a test substance by the present invention comprises the steps of: generating a peroxide from the test substance; obtaining a polymerized substance by bringing an oxidoreductase for producing a polymerized substance and a substrate of the oxidoreductase for producing a polymerized substance into contact with the peroxide; and irradiating the polymerized substance with light to record a temporal variation information of an intensity of scattered light generated from an irradiation point.

Abstract: Compositions and methods for enhancing turfgrass quality and resistance to adverse abiotic conditions are disclosed.

Abstract: The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pKa of benzoic acid. The invention also provides methods of reducing protein degradation by aromatic preservatives in an aqueous formulation of a protein susceptible to such degradation, comprising the step of adding aromatic carboxylate ions to the formulation wherein the formulation is maintained at a pH that is at least 1 unit greater than the pKa of the corresponding aromatic carboxylic acid.

Abstract: Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption.

Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.

Abstract: The invention relates to acetylcholine-producing microorganisms for use in the prevention and/or treatment of intestinal diseases, and/or reduction of risks of intestinal diseases, and/or improvement of intestinal health as well as promoting healthy gut flora. The acetylcholine-producing microorganisms may be provided as a pharmaceutical dosage form or as additive to functional food or food supplemental products. Also encompassed is a method for the production of acetylcholine by use of Lactobacilli. Further the invention refers to microbially produced acetylcholine for use in the treatment and/or prevention of intestinal diseases.

Abstract: Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in PDX mice, back to the original donor patients. This is an approach to personalized cancer therapy, which does not require identification of specific tumor associated antigens. Based on the fundamental principles of immunology, we anticipate that the autoimplanted PDX tumor will stimulate an intense immune response in the original donor patient—including activation of “xenoreactive” lymphocytes and, in turn, a “bystander” activation of anti-tumor immune response lymphocytes, which we anticipate that a response generated in this manner will become systemic and target other similar malignant cells in the patient.

Abstract: Provided herein are methods of producing an acellular tissue product wherein the method can include the step of inducing apoptosis and washing the tissue after induction of apoptosis with a tonic solution. Also provided herein are acellular tissue products produced by the methods provided herein and methods of administering the acellular tissue products to a subject in need thereof.

Abstract: Described herein is a method for blastospore-based insect control products of entomopathogenic fungi including either B. bassiana or I. fumosorosea that produces high concentrations of stable, effective spores by identifying nutritional and environmental conditions required for the rapid production of high concentrations of a stable and infective yeast-like blastospore composition.

Abstract: Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and/or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke.

Abstract: [Problem] Provision of a method for fractionating lipids using liquefied dimethyl ether as a solvent. [Means for Solving] To provide a method for fractionating a lipid using liquefied dimethyl ether as a solvent. [Solution] A method for fractionating a lipid, which comprises subjecting a microbial biomass to extraction using liquefied dimethyl ether as a solvent and then fractionating the lipid utilizing separation selectivity for the lipid. A method for producing a lipid, which comprises subjecting a microbial biomass to extraction using liquefied dimethyl ether as a solvent, then fractionating a portion of the lipid utilizing separation selectivity for the lipid to modify the fatty acid composition of the remainder of the lipid which remains in the microbial biomass, and then extracting the lipid having a modified fatty acid composition.

Abstract: A method of preparing Cordyceps cicadae mycelium active substances for preventing and/or treating xerophthalmia is provided. The method comprises: (a) culturing a Cordyceps cicadae mycelium in a plate media at 15 to 35° C. for 5 to 14 days; (b) inoculating the mycelium of step (a) to a flask containing liquid media and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days; (c) inoculating the mycelium of step (b) to a fermenter tank and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid; (d) freeze-drying and grating the fermentation liquid, so as to obtain a Cordyceps cicadae mycelium powder; (e) extracting the powder with solvent, so as to obtain a Cordyceps cicadae mycelium extract; and (f) drying the extract, so as to obtained the Cordyceps cicadae mycelium active substances.

Abstract: The present invention relates to compositions for weight management comprising: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying component. The composition may also be used for the treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.

Abstract: Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes.

Abstract: Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.

Abstract: A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual.